BioSpace News Archive

Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced the appointment of Dr. Charlie Qi as its Senior Vice President of Global Clinical Development.

Gossamer Bio, Inc. announced that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020, which takes place from September 7th through 9th.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published online in the New England Journal of Medicine.

Study in NEJM, Led by Cincinnati Children’s, Says Inhaled Drug Reduces Need for Invasive Lung Wash

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis will be announced September 8, 2020.

AnHeart Therapeutics, Co., Ltd., a clinical stage oncology company focused on underserved patients in global markets, has through its subsidiary AnHeart Therapeutics Inc. entered into license agreements with Daiichi Sankyo Company, Limited to acquire rights to two novel clinical stage oncology candidates.